PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Recruiting now · Phase 2

Conditions studied: Prostate Cancer (Post Prostatectomy)

In brief

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Key facts

Study ID

NCT06617481

Run by

AdventHealth

People needed

30

Starts

2024-09-20

Expected to finish

2027-10-10

Last updated by the study team

2024-10-24

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
• An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5

You may not qualify if…

• Patients who are planned to have an x-ray contrast agent or other PET radiotracer \& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.
• Patients currently receiving Androgen Deprivation Therapy (ADT).

Where it is running

• AdventHealth — Orlando, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.